Nahoko Uchiyama

2 papers in the library · 62 citations · publishing 2008-2010

Papers

Analysis of Designer Drugs Detected in the Products Purchased in Fiscal Year 2006

YAKUGAKU ZASSHI October 1, 2008 Nahoko Uchiyama, Ruri Kikura-Hanajiri, Nobuo Kawahara et al. 46 citations

In Japan, 32 psychotropic substances were controlled under the Pharmaceutical Affairs Law starting April 2007 to curb drug abuse, but new designer drugs continue to emerge. Just before a law amendment, 7 designer drugs were detected in 15 products using NMR, GC-MS, and LC-MS analyses. These included three methylone derivatives (MDPV, bk-MBDB, bk-MDEA), a MDMA derivative (N-OH MDMA), a methamphetamine derivative (N-Me-4-FMP), a tryptamine derivative (5-MeO-EIPT), and indan-2-amine. 5-MeO-EIPT was newly identified in this study.

DOI: 10.1248/yakushi.128.1499

Analysis of Newly Distributed Designer Drugs Detected in the Products Purchased in Fiscal Year 2008

YAKUGAKU ZASSHI February 1, 2010 Nahoko Uchiyama, Norimasa Miyazawa, Maiko Kawamura et al. 16 citations

By July 2009, Japan had designated 40 psychoactive substances (including 12 tryptamines, 17 phenethylamines, 3 piperazines, 6 alkyl nitrites, 1 diterpene, and 1 plant) as controlled substances under the Pharmaceutical Affairs Law to prevent abuse. Despite these controls, new designer drugs continue to appear in the illegal market. Analysis of two products purchased in Japan between October 2008 and February 2009 identified four compounds: three phenethylamine derivatives—N-Me-2-FMP, ALEPH-4, and DON—and one tryptamine derivative, 5-MeO-EPT. N-Me-2-FMP and 5-MeO-EPT were newly identified, while ALEPH-4 and DON were found as novel illegal drugs in Japan.

DOI: 10.1248/yakushi.130.263 Designer drug Phenethylamines Tryptamines Amine gas treating +3